• By Nilsan Nishotech

---

Pharmaceutical Water Treatment: From Source Water to Point-of-Use Purified Water

A Complete Process Guide | Nilsan Nishotech

---

Introduction: Why Pharmaceutical Water Treatment Matters

Water is the most widely used raw material in pharmaceutical manufacturing. It serves as a solvent, a cleaning agent, a sterilisation medium, and an excipient, and in each role it must meet precise quality standards. A single contamination event traced to sub-standard water can compromise product safety, trigger regulatory action, and halt production entirely.

The pharmaceutical water treatment process is therefore not a utility function but a critical quality system. It must reliably transform raw water regardless of its source variability into grades of water that comply with pharmacopoeial specifications such as the United States Pharmacopeia (USP), European Pharmacopoeia (EP), and World Health Organization (WHO) guidelines.

This article traces the complete journey from the point of raw water intake through every treatment stage to the final point of use, where purified water (PW), water for injection (WFI), or clean steam is delivered to manufacturing operations.

---

1. Raw Water Sources and Their Characteristics

The treatment process begins with an understanding of the feed water, because its composition directly determines the pre-treatment design and the sizing of downstream purification equipment. The three principal sources are:

• Municipal (Potable) Supply: The most common feed source. Typically pre-disinfected with chlorine or chloramines and meets drinking-water standards, but contains dissolved salts, trace organics, and residual disinfectants that must be removed before pharmaceutical use.
• Groundwater (Bore/Well Water): Varies widely by geography. Often high in hardness (calcium and magnesium), iron, manganese, silica, and may contain elevated levels of total dissolved solids (TDS) or nitrates. Requires more intensive pre-treatment.
• Surface Water (Rivers and Lakes): Subject to seasonal turbidity, organic load, algae, and microbiological variation. Demands robust multi-barrier pre-treatment including coagulation, clarification, and media filtration before membrane systems.

Regardless of source, raw water is characterised by parameters including turbidity, TDS, hardness, pH, chlorine/chloramine levels, total organic carbon (TOC), microbial count, and silt density index (SDI) – the last being critical for protecting reverse osmosis (RO) membranes. A thorough feed-water analysis is the mandatory starting point for any system design.

---

2. The Pharmaceutical Water Treatment Process: Stage by Stage

The treatment train converts raw water through a series of progressive purification steps. Each stage addresses a specific category of impurity and protects the equipment downstream. The typical sequence is shown below.

---

Stage 1 – Pre-Treatment

Pre-treatment is the foundation of the entire system. Its purpose is to condition feed water so that advanced membranes and polishing systems are protected from fouling, scaling, and premature degradation.

---

Stage 2 – Reverse Osmosis (RO)

Reverse osmosis is the primary desalination and purification barrier. High pressure drives feed water across a semi-permeable membrane, retaining 95–99% of dissolved salts, heavy metals, bacteria, viruses, pyrogens, and organic molecules above approximately 100 Daltons. The permeate (product water) passes through; the concentrate (reject) is discharged or recycled.

---

Stage 3 – Continuous Electrodeionisation (EDI)

EDI combines ion-exchange resin beds with ion-selective membranes and a direct electrical current to remove the residual ionised species that pass through the RO. Unlike traditional batch deionisation, EDI operates continuously and requires no chemical regeneration, aligning with sustainable pharmaceutical manufacturing practices.

---

Stage 4 – Ultrafiltration (UF) and UV Disinfection

Even after RO and EDI, microbiological control must be actively maintained. UF membranes (typically 5,000–10,000 Dalton molecular weight cut-off) provide a physical barrier to bacteria, bacterial fragments, and endotoxins (pyrogens). UV disinfection at 254 nm destroys the DNA of any viable microorganisms and, at higher doses, can photolytically reduce TOC.

---

Stage 5 – Polishing, Storage, and Distribution Loop

The polishing stage provides a final quality safety net before water enters storage and the distribution loop that delivers it to point-of-use (POU) outlets throughout the facility.

---

3. Grades of Pharmaceutical Water: Definitions and Quality Parameters

The end product of the treatment process must match the pharmacopoeial grade required by the intended application. The four principal grades are summarised below:

Selection of the correct water grade is a regulatory and quality decision. Using PW where WFI is required or designing a system incapable of consistently achieving WFI constitutes a critical GMP non-conformance.

---

4. Monitoring, Compliance, and Continuous Quality Assurance

A pharmaceutical water system is only as reliable as its monitoring programme. Regulatory agencies (FDA, EMA, WHO) expect continuous or frequent in-process monitoring combined with periodic laboratory testing.

Online / In-Line Monitoring Parameters

• Conductivity – measured at each key stage and at POU; alert and action limits are set per USP/EP specifications
• TOC – continuously monitored to ensure organic impurity control
• Temperature – critical for hot-loop WFI systems and for detecting sanitisation cycle performance
• Flow rate and pressure differential – indicates membrane fouling or filter blockage before quality impact occurs
• UV intensity – confirms lamp efficacy in UV units

Periodic Laboratory Testing

• Microbial count (Total Viable Count / Bioburden) at defined POU and system points
• Endotoxin testing (Limulus Amebocyte Lysate / Recombinant Factor C assay) for WFI and HPW
• TOC verification by offline analyser
• Heavy metals and elemental impurities (ICH Q3D compliance)
• Nitrates, heavy metals, and specific chemical impurities per pharmacopoeial monographs

Regulatory Standards

All pharmaceutical water systems must demonstrate compliance with the applicable pharmacopoeia. Key references include USP <1231> Water for Pharmaceutical Purposes, EP 0169 (Purified Water) and EP 0169 (WFI), and WHO Technical Report Series guidance on water quality. Validated systems must be qualified (IQ, OQ, PQ) and supported by a documented change-control and periodic re-qualification programme.

---

5. System Design Principles and Best Practices

Designing a pharmaceutical water treatment system requires integrating process engineering, material science, regulatory knowledge, and risk management. Key principles include:

• 316L Electropolished Stainless Steel: All wetted surfaces in the purification and distribution system should be 316L SS with a surface finish of Ra ≤ 0.5 µm to prevent microbial adhesion and facilitate cleaning.
• Dead-Leg Minimisation: ISPE guidelines specify that dead-legs (stagnant branches) should not exceed 3× the branch pipe diameter. Longer dead-legs allow biofilm development that cannot be controlled by loop circulation.
• Thermal or Chemical Sanitisation: WFI systems are typically maintained at 80 °C continuously (hot storage and distribution). PW systems may use periodic hot-water or chemical sanitisation (ozone, peracetic acid) on a validated schedule.
• Redundancy and Scalability: Critical components such as RO membranes and UV lamps should have operational redundancy. Systems should be designed for future capacity expansion without a full rebuild.
• Documentation and Validation: Every design decision must be documented in User Requirement Specifications (URS), Design Qualification (DQ), and subsequently verified through IQ/OQ/PQ protocols.

---

Conclusion

The pharmaceutical water treatment process is a multi-stage, meticulously engineered system that transforms variable raw water into a controlled, high-purity resource at every point of use. From the characterization of raw water sources through pre-treatment, reverse osmosis, electrodeionisation, ultrafiltration, UV disinfection, and final polishing, and through sanitisable storage and distribution loops, every step is designed with a single purpose: delivering water that consistently meets the pharmacopoeial grade required for safe pharmaceutical manufacturing.

For manufacturers, a robust water treatment system is a strategic asset. It protects product quality and patient safety, reduces the risk of regulatory observations, and provides the operational reliability that pharmaceutical production demands. As technology advances, systems incorporating real-time analytics, automated sanitisation control, and energy-efficient EDI continue to raise the standard for what is achievable.

---

Get in Touch

For system design consultations and enquiries: info@nilsan-nishotech.com

Learn more: www.nilsannishotech.com